📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Hester Biosciences to Divest 43.81% Stake in Texas Lifesciences for INR 92 Million
Hester Biosciences has announced the divestment of a 43.81% equity stake in its subsidiary, Texas Lifesciences Private Limited (TLPL), for a total consideration of INR 92 million. Following the sale to Ticop Life Private Limited, Hester will retain an 11% stake, and TLPL will cease to be a subsidiary. TLPL reported a turnover of INR 285.89 million in FY 2024-25, though over 97% of its sales were internal to Hester. This move allows Hester to unlock capital while maintaining a strategic business relationship with the entity.
Key Highlights
Divesting 43.81% stake out of 54.81% total holding in Texas Lifesciences Private Limited.
Total aggregate consideration for the sale is INR 92 million.
TLPL's FY 2024-25 turnover was INR 285.89 million with a net worth of INR 134.17 million.
Hester will maintain an 11% equity stake and continue business operations with TLPL.
The transaction is expected to be completed within three months from March 5, 2026.
💼 Action for Investors
Investors should watch for the impact on consolidated margins since TLPL's internal sales were previously eliminated, and monitor the utilization of the INR 92 million proceeds.
Hester Biosciences to Divest 43.81% Stake in Texas Lifesciences for INR 92 Million
Hester Biosciences has approved the divestment of a 43.81% equity stake in its subsidiary, Texas Lifesciences Private Limited (TLPL), for a total consideration of INR 92 million. Following the sale to Ticop Life Private Limited, Hester will retain an 11% stake, and TLPL will no longer be a subsidiary. TLPL reported a turnover of INR 285.89 million in FY 2024-25, though over 97% of its sales were internal to Hester. The transaction is expected to be completed within three months and represents a strategic rationalization of the company's subsidiary portfolio.
Key Highlights
Divesting 43.81% stake in Texas Lifesciences for an aggregate value of INR 92 million
Hester will retain an 11% equity stake and continue business relations with TLPL
TLPL FY 2024-25 turnover was INR 285.89 million with a net worth of INR 134.17 million
Over 97% of TLPL's sales were internal to Hester, resulting in elimination during consolidation
The share transfer transaction is expected to be completed within a 3-month period
💼 Action for Investors
Investors should note this as a portfolio streamlining move that unlocks INR 92 million in cash without significantly impacting consolidated revenue due to the high volume of internal sales. Monitor for any impact on procurement margins as TLPL moves from a subsidiary to an external supplier.
Hester Biosciences Re-appoints Rajiv Gandhi as CEO & MD for 3 Years with 99.54% Approval
Hester Biosciences has announced the successful re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director for a three-year term effective from April 1, 2026. The special resolution was passed via a postal ballot process with an overwhelming 99.54% of valid votes cast in favor. While the promoter group showed 100% support, a significant majority of the small institutional voting block (99.24%) voted against the resolution. This move ensures leadership continuity for the company through March 2029.
Key Highlights
Special resolution for re-appointment of Rajiv Gandhi as CEO & MD passed with 99.54% majority.
The new term is effective for three years from April 1, 2026, to March 31, 2029.
Total valid votes cast represented 4,075,085 shares, with 4,056,419 votes in favor.
Promoter group cast 3,451,082 votes, showing 100% internal support for the leadership.
Public institutional holders showed 99.24% dissent, though this represented only 18,570 shares.
💼 Action for Investors
Investors should take confidence in the leadership continuity which supports long-term strategic stability. No immediate action is required as the current management remains at the helm.
Hester Biosciences Proposes Re-appointment of Rajiv Gandhi as CEO & MD for 3 Years
Hester Biosciences has initiated a postal ballot process to seek shareholder approval for the re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director. The proposed tenure is for three years, spanning from April 1, 2026, to March 31, 2029. This move is intended to ensure leadership continuity, and the resolution is being proposed as a Special Resolution. Shareholders can participate in the remote e-voting process from February 8 to March 9, 2026.
Key Highlights
Proposed re-appointment of Mr. Rajiv Gandhi as CEO & Managing Director for a 3-year term.
The new term is scheduled to run from April 1, 2026, through March 31, 2029.
Remote e-voting period is set for February 8, 2026, to March 9, 2026, with results by March 11.
The resolution requires approval as a Special Resolution via postal ballot.
The cut-off date for shareholder eligibility was fixed as January 30, 2026.
💼 Action for Investors
This is a routine leadership continuity event for the promoter-led company. Investors should support the resolution to maintain management stability, though no immediate impact on stock price is expected.
Hester Biosciences Q3 FY26: PAT Surges 140% YoY; H9N2 Vaccine License Received
Hester Biosciences reported a strong 140% YoY increase in standalone PAT for Q3 FY26, driven by a favorable product mix and cost discipline. While the Poultry Healthcare division grew by 32% in Q3, the Animal Healthcare division saw a 38% decline due to timing delays in government-led immunization programs. The company achieved a major regulatory milestone by receiving manufacturing licenses for the H9N2 Avian Influenza vaccine and successfully capitalized its fill/finish facility, doubling its drug product capacity.
Key Highlights
Standalone PAT increased by 140% YoY in Q3 FY26, supported by improved operational discipline.
Poultry Healthcare division revenue grew 32% in Q3 and 17% over the 9-month period.
Received marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine post-quarter end.
Capitalized a new fill/finish facility from the INR 182 crore CWIP, doubling drug product capacity.
Animal Healthcare revenue declined 38% in Q3 due to tender delays, with recovery expected in Q4 FY26.
💼 Action for Investors
Investors should focus on the upcoming launch of the H9N2 vaccine and the resumption of government immunization tenders in Q4. The doubling of manufacturing capacity positions the company for significant scale-up in both domestic and export markets.
Hester Biosciences Q3 Standalone PAT Jumps 140% to ₹106.7M; Poultry Division Grows 32%
Hester Biosciences reported a robust standalone performance for Q3 FY26, with PAT surging 140% YoY to ₹106.69 million on a 12% revenue increase. The growth was primarily driven by the Poultry Healthcare division, which grew 32%, while the Animal Healthcare division faced a 38% decline due to delayed government tenders. Consolidated PAT for the quarter fell 18% to ₹93.10 million, largely due to losses in the African subsidiary. However, the company has doubled its drug product capacity and expects a strong Q4 as national immunization programs resume.
Key Highlights
Standalone Q3 PAT rose 140% to ₹106.69 million, while standalone revenue grew 12% to ₹703.54 million.
Poultry Healthcare division delivered 32% growth in Q3, supported by a new H9N2 Avian Influenza vaccine license.
Animal Healthcare revenue declined 38% due to deferred government orders, which are scheduled to commence in February 2026.
Consolidated 9M FY26 PAT stands at ₹409.37 million, representing a 50% growth over the previous year.
Capitalized a new fill-finish facility during the quarter, effectively doubling the company's drug product capacity.
💼 Action for Investors
Investors should view the standalone margin expansion and poultry segment growth as positive indicators of operational efficiency. The temporary dip in animal healthcare revenue is expected to reverse in Q4, making the current performance a strong base for year-end results.
Hester Biosciences Q3 Standalone PAT Surges 140% YoY to ₹106.7 Mn; CEO Re-appointed
Hester Biosciences delivered a robust standalone performance for Q3 FY26, with Net Profit jumping 140% YoY to ₹106.69 million. Standalone revenue grew by 12% YoY, driven primarily by a 32% growth in the Poultry Healthcare segment. However, consolidated PAT declined by 18% YoY to ₹93.10 million, largely due to a sharp reduction in 'Other Income' compared to the previous year. The board also confirmed the re-appointment of founder Rajiv Gandhi as CEO and Managing Director for a three-year term starting April 2026.
Key Highlights
Standalone Revenue from Operations increased 12% YoY to ₹703.54 million in Q3 FY26.
Standalone Net Profit (PAT) rose 140% YoY to ₹106.69 million from ₹44.39 million.
Poultry Healthcare segment revenue grew 32% YoY to ₹513.02 million.
Consolidated PAT fell 18% YoY to ₹93.10 million, impacted by lower other income of ₹6.69 million vs ₹78.09 million YoY.
Mr. Rajiv Gandhi re-appointed as CEO & Managing Director for 3 years effective April 1, 2026.
💼 Action for Investors
Investors should take note of the strong operational recovery in the standalone business and the significant growth in the poultry segment. The re-appointment of the founder-CEO ensures leadership continuity, making the stock a 'Watch' for sustained margin improvement.
Hester Biosciences Receives Manufacturing License for H9N2 Avian Influenza Vaccine
Hester Biosciences has received a manufacturing license from the Food & Drugs Control Administration for its Low Pathogenic Avian Influenza (H9N2) vaccine for poultry. The H9N2 strain is a persistent challenge in the poultry industry, causing significant economic losses through reduced egg production and broiler performance. This vaccine was developed using technology acquired from ICAR-NIHSAD via Agrinnovate India. This regulatory milestone strengthens Hester's poultry healthcare portfolio and addresses a year-round comorbidity issue in the sector.
Key Highlights
Received manufacturing and marketing license from FDCA for Inactivated Avian Influenza H9N2 vaccine.
Technology for the vaccine was acquired from ICAR-NIHSAD through Agrinnovate India.
Targets the H9N2 strain which causes significant economic losses in both layer and broiler poultry segments.
The vaccine aims to prevent irreversible drops in egg production and high mortality rates associated with the virus.
Strengthens the company's prevention-led poultry healthcare product pipeline.
💼 Action for Investors
Investors should view this as a positive development that expands Hester's product offerings in the animal healthcare market. Monitor the commercial launch timeline and the subsequent impact on the poultry segment's revenue growth.